ArticleBiochemistry and biophysics reports2026
Deletion of TOP2B promoter using CRISPR-Cas9 induces senescence in HEK 293T cells.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA topoisomerase II beta (TOP2B) is crucial for the regulation of DNA topology, transcription, and genome stability. While its function has been extensively studied in post-mitotic cells such as neurons and cardiomyocytes, its role in proliferative cells, especially in the context of cellular senescence and aging, remains inadequately understood. Emerging evidence suggests that TOP2B expression declines with age and is implicated in several age-associated disorders, yet the molecular basis of its involvement in senescence remains poorly understood. In this investigation, we have specifically disrupted the promoter region of TOP2B in HEK 293T cells using CRISPR-Cas9 genome editing. The targeted region, spanning -533 to -481, which encompasses binding motifs for NF-Y and SP1, also accounts for a major proportion of TOP2B promoter activity. Knockout of this regulatory segment resulted in a marked reduction of TOP2B expression. The knockout cells exhibited classical features of senescence, including elevated ROS levels, increased senescence-associated β-galactosidase (SA-β-Gal) activity, and upregulation of key markers such as p53, p21, and p16.To examine the paracrine effects of senescence, conditioned media from TOP2B-deficient cells were given to wild-type HEK 293T cells, which also developed senescence-like phenotypes. These findings suggest that Loss of TOP2B expression is associated with the induction of senescence-like phenotypes in dividing cells and can propagate senescent signaling to neighboring cells. This study highlights a previously underappreciated role of TOP2B in the regulation of cellular aging and opens new avenues for understanding its potential contribution to age-related pathologies in proliferative cell types.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.